{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:40:05Z","timestamp":1787618405703,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cheng Hsin General Hospital, Taiwan","award":["CHGH113-112-N03"],"award-info":[{"award-number":["CHGH113-112-N03"]}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-182-048"],"award-info":[{"award-number":["NSTC 112-2314-B-182-048"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chang Gung University, Taiwan","award":["UMRPD1N0091"],"award-info":[{"award-number":["UMRPD1N0091"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-76270-8","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T06:02:29Z","timestamp":1729836149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nucleos(t)ide analogues potentially activate T lymphocytes through inducing interferon expression in hepatic cells and patients with chronic hepatitis B"],"prefix":"10.1038","volume":"14","author":[{"given":"Ai-Sheng","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungshan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Dong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Lin","family":"Sie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Fen","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"76270_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","volume":"75","author":"MG Martinez","year":"2021","unstructured":"Martinez, M. G., Boyd, A., Combe, E., Testoni, B. & Zoulim, F. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J. Hepatol. 75, 706\u2013717. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.013 (2021).","journal-title":"J. Hepatol."},{"key":"76270_CR2","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto, W. K., Lo, Y. R., Pawlotsky, J. M. & Yuen, M. F. Chronic hepatitis B virus infection. Lancet. 392, 2313\u20132324. https:\/\/doi.org\/10.1016\/S0140-6736(18)31865-8 (2018).","journal-title":"Lancet"},{"key":"76270_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/infdis\/jiv547","volume":"213","author":"KH Liang","year":"2016","unstructured":"Liang, K. H. et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J. Infect. Dis. 213, 966\u2013974. https:\/\/doi.org\/10.1093\/infdis\/jiv547 (2016).","journal-title":"J. Infect. Dis."},{"key":"76270_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.coviro.2016.06.004","volume":"18","author":"F Zoulim","year":"2016","unstructured":"Zoulim, F., Lebosse, F. & Levrero, M. Current treatments for chronic hepatitis B virus infections. Curr. Opin. Virol. 18, 109\u2013116. https:\/\/doi.org\/10.1016\/j.coviro.2016.06.004 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"76270_CR5","doi-asserted-by":"publisher","unstructured":"Chien, R. N. & Liaw, Y. F. Current trend in antiviral therapy for chronic hepatitis B. Viruses 14, doi: (2022). https:\/\/doi.org\/10.3390\/v14020434","DOI":"10.3390\/v14020434"},{"key":"76270_CR6","doi-asserted-by":"publisher","unstructured":"Cathcart, A. L. et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic Hepatitis B infection. Antimicrob. Agents Chemother. 62 https:\/\/doi.org\/10.1128\/AAC.01064-18 (2018).","DOI":"10.1128\/AAC.01064-18"},{"key":"76270_CR7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 49, 1503\u20131514. https:\/\/doi.org\/10.1002\/hep.22841 (2009).","journal-title":"Hepatology"},{"key":"76270_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","volume":"147","author":"CY Wu","year":"2014","unstructured":"Wu, C. Y. et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 147, 143\u2013151e145. https:\/\/doi.org\/10.1053\/j.gastro.2014.03.048 (2014).","journal-title":"Gastroenterology"},{"key":"76270_CR9","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/2012.jama.11975","volume":"308","author":"CY Wu","year":"2012","unstructured":"Wu, C. Y. et al. Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection. Jama. 308, 1906\u20131914. https:\/\/doi.org\/10.1001\/2012.jama.11975 (2012).","journal-title":"Jama"},{"key":"76270_CR10","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/hep.21612","volume":"45","author":"CM Chu","year":"2007","unstructured":"Chu, C. M. & Liaw, Y. F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up. Hepatology. 45, 1187\u20131192. https:\/\/doi.org\/10.1002\/hep.21612 (2007).","journal-title":"Hepatology"},{"key":"76270_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","volume":"7","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Hepatitis B surface antigen levels: Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol. Int. 7, 88\u201397. https:\/\/doi.org\/10.1007\/s12072-012-9343-x (2013).","journal-title":"Hepatol. Int."},{"key":"76270_CR12","doi-asserted-by":"publisher","unstructured":"Xia, Y. & Protzer, U. Control of Hepatitis B Virus by cytokines. Viruses. 9 https:\/\/doi.org\/10.3390\/v9010018 (2017).","DOI":"10.3390\/v9010018"},{"key":"76270_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang, T. T. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 51, 422\u2013430. https:\/\/doi.org\/10.1002\/hep.23327 (2010).","journal-title":"Hepatology"},{"key":"76270_CR14","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/hep.23905","volume":"52","author":"K Wursthorn","year":"2010","unstructured":"Wursthorn, K. et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 52, 1611\u20131620. https:\/\/doi.org\/10.1002\/hep.23905 (2010).","journal-title":"Hepatology"},{"key":"76270_CR15","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","volume":"60","author":"M Buti","year":"2015","unstructured":"Buti, M. et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig. Dis. Sci. 60, 1457\u20131464. https:\/\/doi.org\/10.1007\/s10620-014-3486-7 (2015).","journal-title":"Dig. Dis. Sci."},{"key":"76270_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","volume":"143","author":"C Boni","year":"2012","unstructured":"Boni, C. et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 143, 963\u2013973e969. https:\/\/doi.org\/10.1053\/j.gastro.2012.07.014 (2012).","journal-title":"Gastroenterology"},{"key":"76270_CR17","doi-asserted-by":"publisher","first-page":"110245","DOI":"10.1016\/j.intimp.2023.110245","volume":"119","author":"X Li","year":"2023","unstructured":"Li, X. et al. Tenofovir alters the immune microenvironment of pregnant women with hepatitis B virus infection: Evidence from single-cell RNA sequencing. Int. Immunopharmacol. 119, 110245. https:\/\/doi.org\/10.1016\/j.intimp.2023.110245 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"76270_CR18","doi-asserted-by":"publisher","first-page":"e80585","DOI":"10.1371\/journal.pone.0080585","volume":"8","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One. 8, e80585. https:\/\/doi.org\/10.1371\/journal.pone.0080585 (2013).","journal-title":"PLoS One"},{"key":"76270_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell. Rep. 19, 1189\u20131201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031 (2017).","journal-title":"Cell. Rep."},{"issue":"Suppl 1","key":"76270_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/liv.13627","volume":"38","author":"S Marciano","year":"2018","unstructured":"Marciano, S. & Gadano, A. Why not to stop antiviral treatment in patients with chronic hepatitis B. Liver Int. 38 (Suppl 1), 97\u2013101. https:\/\/doi.org\/10.1111\/liv.13627 (2018).","journal-title":"Liver Int."},{"key":"76270_CR21","doi-asserted-by":"publisher","unstructured":"Luxenburger, H. & Neumann-Haefelin, C. Liver-resident CD8\u2009+\u2009T cells in viral hepatitis: not always good guys. J. Clin. Invest. 133 https:\/\/doi.org\/10.1172\/JCI165033 (2023).","DOI":"10.1172\/JCI165033"},{"key":"76270_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/jvi.77.1.68-76.2003","volume":"77","author":"R Thimme","year":"2003","unstructured":"Thimme, R. et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68\u201376. https:\/\/doi.org\/10.1128\/jvi.77.1.68-76.2003 (2003).","journal-title":"J. Virol."},{"key":"76270_CR23","doi-asserted-by":"publisher","unstructured":"Boni, C. et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143, 963\u2013973 e969, doi: (2012). https:\/\/doi.org\/10.1053\/j.gastro.2012.07.014","DOI":"10.1053\/j.gastro.2012.07.014"},{"key":"76270_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: A complex web of host defenses. Annu. Rev. Immunol. 32, 513\u2013545. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120231 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"76270_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.04321-14","volume":"59","author":"F Guo","year":"2015","unstructured":"Guo, F. et al. STING agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob. Agents Chemother. 59, 1273\u20131281. https:\/\/doi.org\/10.1128\/AAC.04321-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"76270_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu, R., Zhu, B. & Chen, D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell. Mol. Life Sci. 79, 191. https:\/\/doi.org\/10.1007\/s00018-022-04219-z (2022).","journal-title":"Cell. Mol. Life Sci."},{"key":"76270_CR27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 343, 1221\u20131228. https:\/\/doi.org\/10.1126\/science.1243462 (2014).","journal-title":"Science"},{"key":"76270_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1743-422X-11-54","volume":"11","author":"TT Hu","year":"2014","unstructured":"Hu, T. T. et al. Expansion of circulating TFH cells and their associated molecules: Involvement in the immune landscape in patients with chronic HBV infection. Virol. J. 11, 54. https:\/\/doi.org\/10.1186\/1743-422X-11-54 (2014).","journal-title":"Virol. J."},{"key":"76270_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/liv.13475","volume":"38","author":"AK Vyas","year":"2018","unstructured":"Vyas, A. K., Sharma, B. C., Sarin, S. K. & Trehanpati, N. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients. Liver Int. 38, 38\u201349. https:\/\/doi.org\/10.1111\/liv.13475 (2018).","journal-title":"Liver Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76270-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76270-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76270-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T06:04:40Z","timestamp":1729836280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76270-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76270"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76270-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human study was approved by the regulatory authorities and Institutional Review Boards at Cheng Hsin General Hospital, Taipei, Taiwan ((978)111\u00a0A-56). Signed and informed written consent were obtained from all participants, and all research was performed under the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25286"}}